Category: Adestia Therapeutics

  • GSK closes 2020 with multi-million deal frenzy to bolster pipeline

    GlaxoSmithKline has closed the year with a flurry of deals, leaving its development pipeline bulging like Santa’s sack as chief scientific officer Hal Barron pursues a strategy to develop “transformational medicines”. Barron took over as GSK’s CSO in 2018 under instructions from CEO Emma Walmsley to revamp the company’s flagging R&D effort. Since then Barron […]